This article is more than 5 years old. Information may no longer be current.
Baseline status may not affect outcomes of fluocinolone acetonide intravitreal insert
Click Here to Manage Email Alerts
CHICAGO — Baseline best corrected visual acuity, vitreous haze, OCT and other factors do not appear to have an impact on outcomes of patients who receive a fluocinolone acetonide intravitreal insert, according to a speaker here.
“The subgroup analysis shows us that the baseline status does not appear to impact the overall result and the rate of recurrence [of uveitis],” Quan Dong Nguyen, MD, said at the American Academy of Ophthalmology meeting.
The double-masked, prospective, sham-controlled study included 129 patients with noninfectious posterior uveitis who underwent 2:1 randomization to receive a 0.18 mg fluocinolone acetonide intravitreal insert or sham treatment, Nguyen said.
At 6 months, researchers evaluated the effect of baseline variables on the treatment outcomes and recurrence of uveitis.
The insert significantly reduced uveitis recurrence rates at 6 months, with 72.4% of insert patients experiencing no recurrence compared with 9.5% of sham patients, Nguyen said.
Duration of the disease, baseline lens status, baseline noninfectious posterior uveitis treatment, baseline BCVA, baseline OCT and baseline vitreous haze did not appear to affect uveitis recurrence rates.
“The visual acuity improvements seem to also get better with the implant,” Nguyen said. – by Robert Linnehan
Reference:
Nguyen QD. Impact of baseline status on outcomes of fluocinolone acetonide intravitreal insert for noninfectious posterior uveitis. Presented at: American Academy of Ophthalmology meeting; Oct. 27-30, 2018; Chicago.
Disclosure: Nguyen reports he receives institutional research support from EyePoint and is a member of the advisory board for EyePoint.